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Commentary:  
Withholding treatment from a drug addict: poor prognosis or just deserts?   
    
Piers Benn 
 
 
It is good that an ethics consultation was requested in this case. To begin with, some further 
information would help. We are told that Mr H has a ‘history’ of methamphetamine use - but not 
the extent of it, his periods of abstinence, or the length of relapses. It would also be helpful to 
know about his past hospitalizations  – for example, were they for detoxification, or to treat the 
heart condition, or both? There is initially a clear suggestion that he is at serious risk of death if 
he doesn’t receive a transplant – which is surely a powerful prima facie reason for giving him 
one, if possible. But if this really is no longer on the cards, it is especially important to consider 
the LVAD option. It should also be asked whether a transplant could be considered for after an 
LVAD, especially if Mr H can demonstrate his willingness to maintain abstinence. All resource 
and cost implications should be spelled out explicitly. 
 
Additionally, we need more information about the patient’s lack of ‘cognitive awareness’, that 
prevents him from participating in discussions of his treatment options. On what criteria was this 
judgement reached? Is it likely to persist for long, or is it a temporary result of his acute clinical 
condition? Finally, it would be good to have more information about his wife’s ability to fulfill 
her claim to be ‘a committed and capable care-giver’, especially in view of the fact that she is 
soon to have a sixth child. 
 
More centrally, the reason given for rejecting both the transplant option, and eventually the 
LVAD option, is the patient’s history of methamphetamine use. The doctors  need to ask clearly 
and honestly in what way(s), if any, this is genuinely relevant to his treatment. Two possible 
reasons suggest themselves, though there may be others. The first and most obvious reason 
concerns prognosis: i.e. that his past drug use, and/or the likelihood of future drug use, make the 
prospect of the success of these interventions unlikely. The other possible reason (which the 
doctors may be reluctant to acknowledge) is that a history of harmful drug use makes the patient 
a relatively undeserving candidate for complicated and no doubt expensive treatment. It might be 
thought  unfair on patients who have not brought their health problems upon themselves, if they 
are given equal consideration for treatment to those who have caused their own problems by 
their behavior. People whose problems were not caused by irresponsible choices are not 
responsible for their need for treatment. They may therefore be thought more deserving of 
treatment. 
 
Perhaps the cardiologist genuinely thinks that prognosis is the only issue. However, he/she 
should ask whether this might be a smoke-screen for a more ‘punitive’ attitude – which may be 
hard to admit to. What would the team’s view of treatment be, if faced with a similar case of 
CHF, but where there is no history of drug use or other risky behavior? Indeed, what would be 
their view be of a patient who has knowingly and voluntarily allowed his or her health problems 
to come about, but incurred them while doing something admirable, such as looking after people 
with infectious diseases? What about a patient with a similar prognosis (both with and without a 
transplant or LVAD) as Mr H, but who also has an unrelated condition that is likely to cause 
death in the not-too-distant future? Asking questions like this may help doctors recognize a 
punitive dimension to their decision-making, if it exists. 
 
If there is a punitive aspect, then can this be defended? A possible argument is that we each have 
a duty to minimize our need of medical treatment, in order to make room for patients who are 
genuinely unable to avoid needing treatment. This duty needs to be backed up by a sanction – 
namely, that (say) drug users should be given a lower priority for treatment, than others. 
However, to operate fairly, this policy should be transparent rather than covert. And even then, it 
would be extremely difficult to decide which lifestyle criteria to operate. Even if one could, in 
theory, operate such a system, it would soon become enormously complicated and arbitrary.  
 
Besides, it is clear that this patient is in great need, and need should be a paramount 
consideration. This brings us back to the difference the possible treatments would make to his 
prognosis. This question is particularly pertinent with respect to the LVAD. Can the cardiologist 
really say that such a treatment would be entirely futile, due to Mr H’s drugs history? It is 
possible that Mr H has already damaged his heart so much by his drug use that a LVAD would 
be of no significant net benefit to him – even if he abstains from drugs in future. But another 
possibility is that although a LVAD would be of significant net benefit if he remains permanently 
abstinent, his chances of remaining abstinent are judged to be low. A history of repeated relapse 
might be considered good grounds for this prediction. 
 
If the decision not to offer LVAD is based on a prediction of future harmful drug use, the team 
needs to be very sure that this prediction is well grounded, given the enormous harm – the 
patient’s decline and death – that the treatment might prevent. It is, I suspect, very hard to make 
accurate predictions of a patient’s prospects of abstinence or relapse. Mr H’s presumed insights 
into addiction are probably not sufficient to prevent relapse, since relapse is (arguably) a 
conscious choice to use drugs again, for the pleasure it brings, in spite of knowing the dangers. 
At the same time, we must remember that many people do recover from serious addictions,  
because they eventually decide that enough is enough. If or when Mr H becomes aware of the 
very serious threat to his life that his drug use poses, we cannot rule out that he will make this 
decision. 
 
A further important point is that expected treatment/non-treatment outcomes lie on a continuum, 
whether in terms of likelihood and/or degree of benefit. If Mr H has a 50% chance of significant, 
even if sub-optimal benefit from treatment, this should be taken seriously, especially if the 
alternative is a likely early death. 
 
I suggest then that, at the very least, the LVAD be given to Mr H. If he recovers his competence 
to make decisions, the treatment may give him time to consider the gravity of the situation he is 
in, and perhaps to plan abstinence from drugs more decisively than previously. In view of this 
possibility, and the poor prognosis without treatment, this is the least the team can do. 
